News Scilex Semnur Corporate PresentationApril 15, 2019Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 ProgramMarch 27, 2019Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain ManagementMarch 22, 2019Semnur Pharmaceuticals Begins Pivotal Phase 3 Trial For SP-102 In Patients With Lumbar Radicular Pain/SciaticaJanuary 07, 2018Semnur Pharmaceuticals, Inc., Announces Successful Phase 1 / 2 Trial in Patients with Radicular Pain for Its Lead Product, SP-102June 26, 2017Scintilla Pharmaceuticals, Inc., a Subsidiary of Sorrento Therapeutics, Inc., to Acquire Semnur Pharmaceuticals, Inc. to Further Deepen its Pain Management PipelineAugust 15, 2016Top 30 Life Science Startups To Watch In The U SOctober 23, 2014TiE50 Awards Program 2014 Winners Includes Semnur PharmaceuticalsMay 16, 2014
